A selective cellular screening assay for B-Raf and c-Raf kinases

Journal of Biomolecular Screening

Volumn 12, Issue 6, 2007, Pages 818-827

  Ishii, Tsuyoshi ^a   Sootome, Hiroshi ^a   Yagi, Yukiko ^a   Yamashita, Keizo ^a   Noumi, Takato ^a   Noro, Nobuhiro ^a  

^a Development and Medical Affairs Division   (Japan)

Author keywords

B Raf; c Raf; Cell based assay; GeneSwitch ; Raf 1

Indexed keywords

B RAF KINASE; MIFEPRISTONE; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; PHOSPHOTRANSFERASE INHIBITOR; RAF PROTEIN;

ARTICLE; CATALYSIS; CELL ACTIVITY; CELL ASSAY; CELL SCREENING; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS;

CELLS, CULTURED; DRUG EVALUATION, PRECLINICAL; FEASIBILITY STUDIES; HUMANS; MAP KINASE KINASE 1; PHOSPHORYLATION; POINT MUTATION; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS B-RAF; PROTO-ONCOGENE PROTEINS C-RAF; SUBSTRATE SPECIFICITY;

EID: 34548332483     PISSN: 10870571     EISSN: 1552454X     Source Type: Journal    
DOI: 10.1177/1087057107302308     Document Type: Article

References (32)

1. Marais R., Light Y., Paterson HF, Mason CS, Marshall CJ: Differential regulation of Raf-1, A-Raf, and B-Raf by oncogenic ras and tyrosine kinases. J Biol Chem 1997 ; 272: 4378-4383.
2. Davies H., Bignell GR, Cox C., Stephens P., Edkins S., Clegg S.,, et al. Mutations of the BRAF gene in human cancer. Nature 2002 ; 417: 949-954.
3. Kimura ET, Nikiforova MN, Zhu Z., Knauf JA, Nikiforov YE, Fagin JA: High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res 2003 ; 63: 1454-1457.
4. Rajagopalan H., Bardelli A., Lengauer C., Kinzler KW, Vogelstein B., Velculescu VE: Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature 2002 ; 418: 934.
5. Garnett MJ, Marais R.: Guilty as charged: B-RAF is a human oncogene. Cancer Cell 2004 ; 6: 313-319.
6. Kolch W.: Meaningful relationships: the regulation of the Ras/Raf/ MEK/ERK pathway by protein interactions. Biochem J 2000 ; 351 (pt 2). 289-305.
7. Hall-Jackson CA, Eyers PA, Cohen P., Goedert M., Boyle FT, Hewitt N.,, et al. Paradoxical activation of Raf by a novel Raf inhibitor. Chem Biol 1999 ; 6: 559-568.
8. Hall-Jackson CA, Goedert M., Hedge P., Cohen P.: Effect of SB 203580 on the activity of c-Raf in vitro and in vivo. Oncogene 1999 ; 18: 2047-2054.
9. Wilhelm SM, Carter C., Tang L., Wilkie D., McNabola A., Rong H.,, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004 ; 64: 7099-7109.
10. McCubrey JA, Steelman LS, Hoyle PE, Blalock WL, Weinstein-Oppenheimer C., Franklin RA,, et al. Differential abilities of activated Raf oncoproteins to abrogate cytokine dependency, prevent apoptosis and induce autocrine growth factor synthesis in human hematopoietic cells. Leukemia 1998 ; 12: 1903 -1929.
11. Lewis TS, Shapiro PS, Ahn NG: Signal transduction through MAP kinase cascades. Adv Cancer Res 1998 ; 74: 49-139.
12. Hazen RJ, Harvey RJ, St Clair MH, Ferris RG, Freeman GA, Tidwell JH,, et al. Anti-human immunodeficiency virus type 1 activity of the nonnucleoside reverse transcriptase inhibitor GW678248 in combination with other antiretrovirals against clinical isolate viruses and in vitro selection for resistance. Antimicrob Agents Chemother 2005 ; 49: 4465-4473.
13. Takle AK, Brown MJ, Davies S., Dean DK, Francis G., Gaiba A.,, et al. The identification of potent and selective imidazole-based inhibitors of B-Raf kinase. Bioorg Med Chem Lett 2006 ; 16: 378-381.
14. King AJ, Patrick DR, Batorsky RS, Ho ML, Do HT, Zhang SY,, et al. Demonstration of a genetic therapeutic index for tumors expressing oncogenic BRAF by the kinase inhibitor SB-590885. Cancer Res 2006 ; 66: 11100-11105.
15. Dean DK, Takle AK, Wilson DM: Imidazole derivatives as Raf kinase inhibitors. W002/24680 2002.
16. Alessi DR, Cuenda A., Cohen P., Dudley DT, Saltiel AR: PD 098059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in vivo. J Biol Chem 1995 ; 270: 27489-27494.
17. Favata MF, Horiuchi KY, Manos EJ, Daulerio AJ, Stradley DA, Feeser WS,, et al. Identification of a novel inhibitor of mitogen-activated protein kinase kinase. J Biol Chem 1998 ; 273: 18623-18632.
18. Mason CS, Springer CJ, Cooper RG, Superti-Furga G., Marshall CJ, Marais R.: Serine and tyrosine phosphorylations cooperate in Raf-1, but not B-Raf activation. Embo J 1999 ; 18: 2137-2148.
19. Senner V., Sotoodeh A., Paulus W.: Regulated gene expression in glioma cells: a comparison of three inducible systems. Neurochem Res 2001 ; 26: 521-524.
20. Abruzzese RV, Godin D., Mehta V., Perrard JL, French M., Nelson W.,, et al. Ligand-dependent regulation of vascular endothelial growth factor and erythropoietin expression by a plasmid-based autoinducible GeneSwitch system. Mol Ther 2000 ; 2: 276-287.
21. Ravi RK, Weber E., McMahon M., Williams JR, Baylin S., Mal A.,, et al. Activated Raf-1 causes growth arrest in human small cell lung cancer cells. J Clin Invest 1998 ; 101: 153-159.
22. Wan PT, Garnett MJ, Roe SM, Lee S., Niculescu-Duvaz D., Good VM,, et al. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 2004 ; 116: 855-867.
23. Dhillon AS, Meikle S., Peyssonnaux C., Grindlay J., Kaiser C., Steen H.,, et al. A Raf-1 mutant that dissociates MEK/extracellular signal-regulated kinase activation from malignant transformation and differentiation but not proliferation. Mol Cell Biol 2003 ; 23: 1983 -1993.
24. Adler V., Qu Y., Smith SJ, Izotova L., Pestka S., Kung HF,, et al. Functional interactions of Raf and MEK with Jun-N-terminal kinase (JNK) result in a positive feedback loop on the oncogenic Ras signaling pathway. Biochemistry 2005 ; 44: 10784-10795.
25. Terai K., Matsuda M.: Ras binding opens c-Raf to expose the docking site for mitogen-activated protein kinase kinase. EMBO Rep 2005 ; 6: 251-255.
26. Chong H., Lee J., Guan KL: Positive and negative regulation of Raf kinase activity and function by phosphorylation. Embo J 2001 ; 20: 3716-3727.
27. Cohen P.: The development and therapeutic potential of protein kinase inhibitors. Curr Opin Chem Biol 1999 ; 3: 459-465.
28. Knight ZA, Shokat KM: Features of selective kinase inhibitors. Chem Biol 2005 ; 12: 621-637.
29. Cheng Y., Prusoff WH: Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 1973 ; 22: 3099-3108.
30. Davies SP, Reddy H., Caivano M., Cohen P.: Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J 2000 ; 351: 95-105.
31. Newbatt Y., Burns S., Hayward R., Whittaker S., Kirk R., Marshall C.,, et al. Identification of inhibitors of the kinase activity of oncogenic V600E BRAF in an enzyme cascade high-throughput screen. J Biomol Screen 2006 ; 11: 145-154.
32. Menjivar M., Ortiz G., Cardenas M., Garza-Flores J.: Comparison of the DELFIA and RIA methods for measuring luteinizing and follicle stimulating hormones in serum [in Spanish]. Rev Invest Clin 1993 ; 45: 579-584.